Neonatal sepsis workups in infants >/=2000 grams at birth: A population-based study.
BACKGROUND
Few data are available on the outcome of neonatal sepsis evaluations in an era when intrapartum antibiotic therapy is common.


METHODS
We identified all newborns weighing >/=2000 g at birth who were ever evaluated for suspected bacterial infection at 6 Kaiser Permanente hospitals between October 1995 and November 1996, reviewed their records and laboratory data, and tracked them to 1 week after discharge. We analyzed the relationship between key predictors and the presence of neonatal bacterial infection.


RESULTS
Among 18 299 newborns >/=2000 g without major congenital anomalies, 2785 (15.2%) were evaluated for sepsis with a complete blood count and/or blood culture. A total of 62 (2.2%) met criteria for proven, probable, or possible bacterial infection: 22 (.8%) had positive cultures and 40 (1.4%) had clinical evidence of bacterial infection. We tracked all but 10 infants (.4%) to 7 days postdischarge. There were 67 rehospitalizations (2.4%; 2 for group B streptococcus bacteremia). Among 1568 infants who did not receive intrapartum antibiotics, initial asymptomatic status was associated with decreased risk of infection (adjusted odds ratio [AOR]:.26; 95% confidence interval [CI]:.11-.63), while chorioamnionitis (AOR: 2. 40; 95% CI: 1.15-5.00), low absolute neutrophil count (AOR: 2.84; 95% CI: 1.50-5.38), and meconium-stained amniotic fluid (AOR: 2.23; 95% CI: 1.18-4.21) were associated with increased risk. Results were similar among 1217 infants who were treated, except that maternal chorioamnionitis was not significantly associated with neonatal infection.


CONCLUSIONS
The risk of bacterial infection in asymptomatic newborns is low. Evidence-based observation and treatment protocols could be defined based on a limited set of predictors: maternal fever, chorioamnionitis, initial neonatal examination, and absolute neutrophil count. Many missed opportunities for treating mothers and infants exist.
Escobar
G J
GJ
Kaiser Permanente Medical Care Program, Division of Research, Perinatal Research Unit, Oakland, California 94611, USA. gabriel.escobar@ncal.kaiperm.org
Li
D K
DK
Armstrong
M A
MA
Gardner
M N
MN
Folck
B F
BF
Verdi
J E
JE
Xiong
B
B
Bergen
R
R
D000667:Ampicillin / Q000008:administration & dosage; D001431:Bacteriological Techniques; D002511:Cephalosporins / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000175:diagnosis* / Q000517:prevention & control; D010359:Patient Readmission; D011446:Prospective Studies; D012307:Risk Factors; D018805:Sepsis / Q000175:diagnosis* / Q000517:prevention & control; D013290:Streptococcal Infections / Q000175:diagnosis / Q000517:prevention & control; D013292:Streptococcus agalactiae
D002511:Cephalosporins; D000667:Ampicillin